Number of participants with normal physical joint function ‐ normal function at 12 months of · septic arthritis in children taking antibiotics
Corticosteroids (dexamethasone) may leads to higher number of participants with normal physical joint function ‐ normal… compared with placebo (low certainty).
1 finding from 1 review
Number of days of antibiotic treatment ‐ number of days of intravenous antibiotic treatment · septic arthritis in children taking antibiotics
Corticosteroids (dexamethasone) showed no clear difference in number of days of antibiotic treatment ‐ number of days of… compared with placebo (low certainty).
1 finding from 1 review
Length of hospital stay · septic arthritis in children taking antibiotics
1 finding from 1 review
Total adverse events at 12 months · septic arthritis in children taking antibiotics
1 finding from 1 review
Serious adverse events at 12 months · septic arthritis in children taking antibiotics
1 finding from 1 review
Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether intralesional dexamethasone injections changes maximal mouth opening (interincisal distance) compared with placebo injections (very low certainty).
2 findings from 1 review
Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether intralesional dexamethasone injections changes burning sensation (VAS 0-100) compared with placebo injections (very low certainty).
2 findings from 1 review
MD -52.00 [-62.04, -41.96]
1 study · 25 participants
Very low
MD -46.00 [-53.44, -38.56]
1 study · 25 participants
Very low
Adverse effects · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Change in grip strength · patients with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Sleeplessness · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone may leads to lower sleeplessness compared with oral prednisolone (low certainty).
1 finding from 1 review
Moon facies · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone probably leads to lower moon facies compared with oral prednisolone (moderate certainty).
1 finding from 1 review
Change in disability after one year · patients with chronic inflammatory demyelinating polyradiculoneuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone probably leads to higher remission at 12 months compared with oral prednisolone (moderate certainty).
1 finding from 1 review
≥ 1 point improvement on INCAT disability score at 12 months · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone may leads to higher ≥ 1 point improvement on INCAT disability score at 12 months compared with oral prednisolone (low certainty).
1 finding from 1 review
Change in MRC sum score · patients with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
Cataract progression · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher cataract progression ‐ 12 to 24 months compared with intravitreal antiVEGF (moderate certainty).
1 finding from 1 review
RR 4.23 [2.36, 7.59]
Studies not reported
Moderate
Use of IOP‐lowering medications ‐ 24 months · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher use of IOP‐lowering medications ‐ 24 months compared with intravitreal antiVEGF (moderate certainty).
1 finding from 1 review
RR 4.76 [2.84, 7.99]
Studies not reported
Moderate
Surgery for glaucoma ‐ 24 months · macular edema in diabetes
It is very uncertain whether intravitreal dexamethasone implant 0.7 mg changes surgery for glaucoma ‐ 24 months compared with intravitreal antiVEGF (very low certainty).
1 finding from 1 review
RR 3.02 [0.12, 73.56]
Studies not reported
Very low